Hostname: page-component-745bb68f8f-v2bm5 Total loading time: 0 Render date: 2025-02-10T12:18:55.987Z Has data issue: false hasContentIssue false
  • English
  • Français

History Teaches Us That Confronting Antibiotic Resistance Requires Stronger Global Collective Action

Published online by Cambridge University Press:  01 January 2021

Scott H. Podolsky ,
Robert Bud ,
Christoph Gradmann ,
Bård Hobaek ,
Claas Kirchhelle ,
Tore Mitvedt ,
María Jesús Santesmases ,
Ulrike Thoms ,
Dag Berild  and
Anne Kveim Lie
Get access Rights & Permissions [Opens in a new window]

Extract

Antibiotic development and usage, and antibiotic resistance in particular, are today considered global concerns, simultaneously mandating local and global perspectives and actions. Yet such global considerations have not always been part of antibiotic policy formation, and those who attempt to formulate a globally coordinated response to antibiotic resistance will need to confront a history of heterogeneous, often uncoordinated, and at times conflicting reform efforts, whose legacies remain apparent today. Historical analysis permits us to highlight such entrenched trends and processes, helping to frame contemporary efforts to improve access, conservation and innovation.

Type
JLME Supplement
Information
Journal of Law, Medicine & Ethics , Volume 43 , Issue S3 , Autumn 2015 , pp. 27 - 32
Copyright
Copyright © American Society of Law, Medicine and Ethics 2015

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Bud, R., Penicillin: Triumph and Tragedy (New York: Oxford University Press, 2007).Google Scholar
Batten, L. W., “Discussion on the Use and Abuse of Antibiotics,” Proceedings of the Royal Society of Medicine 48 (1955): 355–364.Google Scholar
See, e.g., Jawetz, E. Marshall, M. S., “The Role of the Laboratory in Antibiotic Therapy,” Journal of Pediatrics 37, no. 4 (1950): 545–554.CrossRefGoogle Scholar
Jawetz, E., “Patient, Doctor, Drug, and Bug,” Antibiotics Annual (1957–1958): 287–295.Google Scholar
Podolsky, S. H., The Antibiotic Era: Reform, Resistance, and the Pursuit of a Rational Therapeutics (Baltimore: Johns Hopkins University Press, 2015): At 43–87.Google Scholar
Temko, S., oral arguments “In the Matter of Novobiocin-Tetracycline Drugs; Calcium Novobiocin-Sulfamethizole Tablets (Upjohn Co.), Arlington, VA, August 13, 1969,” Box 88-78-36, FDA Division of Dockets Management, Rockville, Maryland.Google Scholar
See Podolsky, , supra note 5, at 112–139.Google Scholar
Negotiations of the Storting (Norwegian Parliament): Ot.prp.51 1928; Ot.prp.50 1938. See also Andrew, M. Jøldal, B. Tomson, G., “Norway's National Drug Policy. Its Evolution and Lessons for the Future,” Development Dialogue 1 (1995): 25–53.Google Scholar
Kveim Lie, A., “Producing Standards, Producing the Nordic Region: Antibiotic Susceptibility Testing, from 1950–1970,” Science in Context 27, no. 2 (2014): 215–248.Google Scholar
“Meetings of the Director of Health and His Expert Council,” 4/22/47, 6/27/47, Archives of the Norwegian Medicines Agency.Google Scholar
See Bud, , supra note 1, at 163–191.Google Scholar
Thoms, U., “Between Promise and Threat: Antibiotics in Food in Germany 1950–1980,” NTM. Zeitschrift für Geschichte der Wissenschaften, Technik und Medizin 20, no. 3 (2012): 181–214.Google Scholar
Kirchhelle, C., Pyrrhic Progress. Antibiotics in Western Food Production (1949–2013), Ph.D. Thesis, Oxford University (forthcoming).Google Scholar
So, A. et al., “One Health Perspective: An Integrated Systems Approach Is Needed to Ensure the Sustainability of Antibiotic Effectiveness for Both Humans and Animals,” Journal of Law, Medicine & Ethics 43, no. 2, Supp. (2015): Available via aslme.org.CrossRefGoogle Scholar
See Bud, , supra note 1, at 75–96; Santesmases, M. J., “Distributing Penicillin: The Clinic, the Hero and Industrial Production in Spain, 1943–1952,” in Quirke, V. Slinn, J., eds., Perspectives on Twentieth-Century Pharmaceuticals (Oxford: Peter Lang, 2010).Google Scholar
“Report to the Director-General, Scientific Group on Antibiotics Research, Geneva, 26–30 May 1959,” Box 10, ff 6, Selman Waksman papers, Rutgers University.Google Scholar
Gradmann, C., “Sensitive Matters: The World Health Organization and Antibiotic Resistance Testing, 1945–1975,” Social History of Medicine 26, no. 3 (2013): 555–574.CrossRefGoogle Scholar
Watanabe, T., “Infective Heredity of Multiple Drug Resistance in Bacteria,” Bacteriological Reviews 27 (1963): 87–115; Osmundsen, J. A., “Are Germs Winning the War against People?” Look (October 18, 1966): 140–141.CrossRefGoogle Scholar
Levy, S. B. Clowes, R. C. Koenig, E. L., eds., Molecular Biology, Pathogenicity, and Ecology of Bacterial Plasmids (New York: Plenum, 1981).Google Scholar
See Podolsky, , supra note 5, at 158–167.Google Scholar
See Bud, , supra note 1, at 196–198.Google Scholar
Lederberg, J. Shope, R. E., eds., Emerging Infections: Microbial Threats to Health in the United States (Washington, D.C.: National Academy Press, 1992).Google Scholar
Gradmann, C., “Re-Inventing Infectious Disease: Antibiotic Resistance and Drug Development at the Bayer Company 1945–1980,” Medical History 60, no. 2 (forthcoming 2016).CrossRefGoogle Scholar
World Health Organization, WHO Global Strategy for Containment of Antibiotic Resistance (Geneva: World Health Organization, 2001).Google Scholar
World Health Organization, Antimicrobial Resistance: Global Report on Surveillance (Geneva: World Health Organization, 2014).Google Scholar